Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan and Sunitinib in Relapsed or Refractory Osteosarcoma
NCT03900793Phase 1Recruiting
- Sponsor
- University of Colorado Denver
- Start
- Aug 2019
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of losartan and sunitinib in osteosarcoma (OS), sponsored by University of Colorado Denver. Primary endpoints: Dose-Limiting Toxicities up to 4 years, Maximally Tolerated Dose up to 4 years and 1 more. Started Aug 2019; status: recruiting.
02
Drugs
losartansunitinib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT03900793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03900793.